Journal article
Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme
Journal of neuro-oncology, v 117(1), pp 125-131
01 Mar 2014
PMID: 24442482
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Retrospective data suggests that low serum glucose levels during the treatment of glioblastoma multiforme (GBM) may improve clinical outcomes. As such, many patients are implementing a ketogenic diet (KD) in order to decrease serum glucose flux while simultaneously elevating circulating ketones during radiation therapy and chemotherapy for the treatment of GBM. With IRB approval, a retrospective review of patients with high-grade glioma treated with concurrent chemoradiotherapy and adjuvant chemotherapy was carried out from August 2010 to April 2013. Serum glucose and ketone levels, dexamethasone dose, and toxicity of patients undergoing a KD during treatment were also assessed. Blood glucose levels were compared between patients on an unspecified/standard diet and a KD. Toxicity was assessed by Common Terminology Criteria for Adverse Events version 4. In total, 53 patients were analyzed. Six underwent a KD during treatment. The diet was well tolerated with no grade III toxicity and one episode of grade II fatigue. No episodes of symptomatic hypoglycemia were experienced. Four patients are alive at a median follow-up of 14 months. The mean blood glucose of patients on a standard diet was 122 versus 84 mg/dl for those on a KD. Based on this retrospective study, a KD appears safe and well tolerated during the standard treatment of GBM. Dietary restriction of carbohydrates through a KD reduces serum glucose levels significantly, even in conjunction with high dose steroids, which may affect the response to standard treatment and prognosis. Larger prospective trials to confirm this relationship are warranted.
Metrics
Details
- Title
- Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme
- Creators
- Colin E. Champ - Thomas Jefferson UniversityJoshua D. Palmer - Thomas Jefferson UniversityJeff S. Volek - Department of Kinesiology, University of ConnecticutMaria Werner-Wasik - Thomas Jefferson UniversityDavid W. Andrews - Thomas Jefferson UniversityJames J. Evans - Thomas Jefferson UniversityJon Glass - Thomas Jefferson UniversityLyndon Kim - Thomas Jefferson UniversityWenyin Shi - Thomas Jefferson University
- Publication Details
- Journal of neuro-oncology, v 117(1), pp 125-131
- Publisher
- Springer US
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Radiation Oncology (and Nuclear Medicine)
- Web of Science ID
- WOS:000331964600014
- Scopus ID
- 2-s2.0-84901625233
- Other Identifier
- 991021897382404721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Clinical Neurology
- Oncology